AGXT Inhibitors

Chemical inhibitors of AGXT can effectively prevent the enzyme from performing its biological function by various biochemical means. Glyoxylate, a substrate for AGXT, can cause substrate inhibition at high concentrations, where an excess of substrate hinders the enzyme's catalytic efficiency. Hydroxypyruvate competes with pyruvate for the active site of AGXT, and by outcompeting the natural substrate, it can inhibit the normal function of the enzyme. Oxalate, as a product of AGXT action, can exert product inhibition by accumulating and preventing further enzyme activity.

Phenylhydrazine and divicine target the pyridoxal phosphate group of AGXT. Phenylhydrazine binds irreversibly to this cofactor, leading to enzyme inactivation. Divicine reacts with pyridoxal phosphate, forming a complex that disrupts AGXT's catalytic cycle. Isocarboxazid, although a non-selective monoamine oxidase inhibitor, can modify pyridoxal phosphate and thereby inactivate AGXT. Nitrofurantoin can also form a complex with pyridoxal phosphate, resulting in the inhibition of AGXT. Methotrexate affects folate metabolism, and since folates are necessary for pyridoxal phosphate synthesis, this can indirectly lead to reduced AGXT activity. Glutamate at elevated levels may competitively inhibit AGXT, interfering with the binding of the enzyme's natural substrates. Boric acid can inhibit AGXT by forming complexes with cis-diols, which could interfere with the binding of pyridoxal phosphate to the enzyme. Lastly, acivicin, by mimicking the enzyme's substrates, can bind irreversibly to the active site of AGXT, resulting in its inhibition.